NCT04846478View on ClinicalTrials.gov

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

March 30, 2026

Study Completion Date

September 30, 2026

Conditions
Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Talazoparib

capsule, taken by mouth, once a day

DRUG

Tazemetostat

orally as a tablet twice daily.

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

Epizyme, Inc.
Pfizer
All Listed Sponsors
collaborator

Epizyme, Inc.

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT04846478 - Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | Biotech Hunter | Biotech Hunter